BaladoCritique - club de lecture médical

Dr Luc Lanthier et collaborateurs
  • 0.0 (0)
  • Education

BaladoCritique – club de lecture médical | médecine interne | EBM

  1. Sep 28

    BC 080 – Rivaroxaban puis aspirine vs aspirine seule après une arthroplastie totale de la hanche ou du genou (étude EPCAT-III)

    Dans cette 80e baladodiffusion, les Drs Mathieu Labossière et Alexandre Mutchmore discutent de thromboprophylaxie en chirurgie orthopédique, en plus de réviser la littérature médicale d’août 2026.   Quiz clinique (2 min 05), présentation principale (2 min 38), critique (21 min 51), retour sur le cas clinique (31 min 27), autres articles (32 min 50), réponse au quiz clinique (36 min 19).   Référence principale :   Shivakumar S, Matino D, Zukor D, Kahn SR, Vincent G, Mundi R, et al. Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty. N Engl J Med. 2026. Epub 2026/07/12. doi: 10.1056/NEJMoa2603649. PubMed PMID: 42437501.   Articles associés :   The Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000;355:1295-302. PubMed PMID: 10776741.   Anderson DR, Dunbar MJ, Bohm ER, et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 2013;158(11):800-6. PubMed PMID: 23732713.   Anderson DR, Dunbar M, Murnaghan J, Kahn SR, Gross P, Forsythe M, et al. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. N Engl J Med. 2018;378(8):699-707. PubMed PMID: 29466159.   Anderson DR, Morgano GP, Bennett C, Dentali F, Francis CS, Garcia DA et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv 2019;3(23):3898–3944. PubMed PMID: 31794602.   Sidhu VS, Kelly TL, Pratt N, Graves SE, Buchbinder R, Adie S et al. Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial. JAMA. 2022;328(8):719-727. PubMed PMID: 35997730.   Autres articles d’intérêt récent :   Heerspink HJL, Neuen BL, Agarwal R, Cherney DZI, Lam CSP, Tuttle KR, et al. Finerenone in Persons with Chronic Kidney Disease without Diabetes. N Engl J Med. 2026;395(6):533-45. PubMed PMID: 42246672.   Colson AE, Kumar PN, Ruane PJ, Chetchotisakd P, Ratanasuwan W, Liberty A, et al. Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial. Lancet. 2026;408(10557):821-32. PubMed PMID: 42586113.   Stone JH, Buttgereit F, Saraux A, Schmidt WA, Dejaco C, Spiera R, et al. Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica. N Engl J Med. 2026;395(7):637-47. PubMed PMID: 42234540.   Akerboom B, Martens ESL, Stals MAM, Brouwer RE, Coppens M, Costantino G, et al. YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism in Patients With Cancer: A Randomized Clinical Trial. JAMA. 2026;336(8):655-63. PubMed PMID: 42437322.   Guides de pratique :   Prabhakaran S, Gonzalez NR, Zachrison KS, Adeoye O, Alexandrov AW, Ansari SA, et al. 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2026;57(8):e316-e436. PubMed PMID: 41582814.   Walsh MN, Kober L, Sliwa K, Adamo M, Agarwal A, Banerjee A, et al. AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026). Circulation. 2026;154(7):e279-e93. PubMed PMID: 42366997.   Référence du quiz clinique :   Vaglio A, Peyronel F, Bajema IM, Pegoraro F. Retroperitoneal fibrosis. Lancet. 2026;408(10555):649-664. PubMed PMID: 41905382.

  2. Aug 23

    BC 079 – Daraxonrasib ou chimiothérapie dans le cancer du pancréas métastatique déjà traité (étude RASolute 302)

    Dans cette 79e baladodiffusion, les Drs Luc Lanthier et Giulia Pool discutent d’une nouveauté thérapeutique en cancer du pancréas, en plus de réviser la littérature médicale de mai, juin et juillet 2026.   Quiz clinique (2 min 05), présentation principale (2 min 35), critique (22 min 32), retour sur le cas clinique (28 min 04), autres articles (29 min 32), réponse au quiz clinique (36 min 35).   Référence principale :   O’Reilly EM, Wainberg ZA, Hendifar AE, Borad MJ, Pietrantonio F, Pant S, et al. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. N Engl J Med. 2026;395(4):325-37. PubMed PMID: 42223072.   Articles associés :   Teede HJ, Khomami MB, Morman R, Laven JSE, Joham AE, Costello MF, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026;407(10545):2329-39. PubMed PMID: 42119588.   Stoop TF, Javed AA, Oba A, Koerkamp BG, Seufferlein T, Wilmink JW, et al. Pancreatic cancer. Lancet. 2025;405(10485):1182-202. PubMed PMID: 40187844.   Der CJ, Yeh JJ. Advances in RAS Therapeutics for Pancreatic Cancer. N Engl J Med. 2026;394(18):1857-1861. PubMed PMID: 42090797.   Wolpin BM, Park W, Garrido-Laguna I, Spira A, Starodub A, Sommerhalder D, et al. Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer. N Engl J Med. 2026;394(18):1790-802. PubMed PMID: 42090791.   Sivakumar S. Breaking the RAS Barrier in Pancreatic Cancer. N Engl J Med. 2026;395(4):400-1. PubMed PMID: 42485631.   Aronchik I, Kar S, Zhuang Y, Ahler E, Lai LP, Seshadri V, et al. Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. Nat Med. 2026;32(8):2865-77. PubMed PMID: 42581230.   Autres articles d’intérêt récent :   Rosenfield K, Klok FA, Piazza G, Sharp ASP, Ni Ainle F, Jaff MR, et al. Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism. N Engl J Med. 2026;394(20):1979-90. PubMed PMID: 41910345.   Cummings JL, Atri A, Sano M, Zetterberg H, Scheltens P, Knop FK, et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer’s disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet. 2026;407(10544):2167-79. PubMed PMID: 41865758.   Hayden FG, Shinkai M, Clark TW, Luetkemeyer AF, Sax PE, Hanage WP, et al. Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts. N Engl J Med. 2026;394(19):1905-15. PubMed PMID: 42127390.   Houston BL, McIsaac DI, Breau RH, Kanji S, Greenstreet P, Andrews M, et al. Hospital Policy of Tranexamic Acid to Reduce Transfusion in Major Noncardiac Surgery. N Engl J Med. 2026;394(24):2419-28. PubMed PMID: 42267805.   Hou J, Lim SG, Buti M, Yuen MF, Gane E, Lampertico P, et al. Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection. N Engl J Med. 2026;394(24):2395-406. PubMed PMID: 42206582.   Wazni OM, Chun KRJ, Nair DG, Anic A, Duytschaever M, Chrispin J, et al; AVANT GUARD Study Investigators. Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation. N Engl J Med. 2026;394(24):2407-2418. PubMed PMID: 42041224.   Doshi SK, Kar S, Nair DG, Waggoner T, Agarwal H, Moussavian M, et al. Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation. N Engl J Med. 2026;394(21):2083-94. PubMed PMID: 41910347.   Staphylococcus aureus Network Adaptive Platform Trial G, Lee TC, Barina LA, Walls G, Goodman AL, Yahav D, et al. Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia. N Engl J Med. 2026;394(23):2329-39. PubMed PMID: 42308484.   Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Group. Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial. Lancet. 2026;408(10550):141-152. PubMed PMID: 42309115.   Nathan SD, Smith P, Deng C, King CS, De Salvo M, Weigt SS, et al. Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. N Engl J Med. 2026;395(2):115-26. PubMed PMID: 42149993.   Guides de pratique :   Smolen JS, Edwards CJ, Konzett V, Laskou F, Aletaha D, Caporali R, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. Ann Rheum Dis. 2026;85(6):991-1009. PubMed PMID: 41826212.   Peery AF, Strate LL, Stollman N, Mankaney G, Chang JW, Grover S. ACG Clinical Guideline: Colonic Diverticulitis. Am J Gastroenterol. 2026;121(7):1549-61. PubMed PMID: 42390126.   Writing Committee M, Ndumele CE, Rodriguez F, Dixon DL, Khan SS, Mukherjee D, et al. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;154(4):e50-e158. PubMed PMID: 42263157.   Références du quiz clinique :   Richert Q, Miller N, Cameron S, Barr B, Nkosi J, Sharma A. Updates on Rhabdomyolysis: A Clinically Oriented Narrative Review. Chest. 2026;170(1):128-36. PubMed PMID: 41619932.   Cabral BMI, Edding SN, Portocarrero JP, Lerma EV. Rhabdomyolysis. Dis Mon. 2020;66(8):101015. PubMed PMID: 32532456.

  3. May 20

    BC 078 – Traitement intensif ciblant le cholestérol-LDL dans la maladie cardiovasculaire athérosclérotique (étude Ez-PAVE)

    Dans cette 78e baladodiffusion, les Drs Luc Lanthier et Pierre-Nicolas Perron discutent de traitement intensif de la dyslipidémie, en plus de réviser la littérature médicale d’avril 2026.   Quiz clinique (1 min51), présentation principale (2 min 23), critique (16 min 30), retour sur le cas clinique (22 min 25), autres articles (24 min 32), réponse au quiz clinique (27 min 32).   Référence principale :   Lee YJ, Lee SJ, Kim JW, Lee SH, Kim GS, Park JH, et al; Ez-PAVE Investigators. Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease. N Engl J Med. 2026;394(14):1365-1375. PubMed PMID: 41910315.   Articles associés :    Probstfield JL, Branch KRH. Paving the Road toward Targeted Lipid Lowering. N Engl J Med. 2026 Apr 9;394(14):1443-1444. PubMed PMID: 41910324.   Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, et al; ESC/EAS Scientific Document Group. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359-4378. PubMed PMID: 40878289.   Marston NA, Bohula EA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, et al; VESALIUS-CV Investigators. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial. JAMA. 2026;335(16):1400-1407. PubMed PMID: 41903215.   Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-504. PubMed PMID: 15007110.   LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-35. PubMed PMID: 15755765.   Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-97. PubMed PMID: 26039521.   Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. PubMed PMID: 28304224.   Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-2107. PubMed PMID: 30403574.   Autres articles d’intérêt récent :    Landmesser U, Skurk C, Kirchhof P, Lewalter T, Hartung J, Rroku A, et al; CLOSURE-AF Trial Investigators. Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation. N Engl J Med. 2026;394(13):1270-1280. PubMed PMID: 41849741.   Choi KH, Kang D, Kim W, Doh JH, Kim J, Park YH, et al; SMART-DECISION Investigators. Discontinuation of Beta-Blocker Therapy after Myocardial Infarction. N Engl J Med. 2026;394(13):1302-1312. PubMed PMID: 41910427.   Sharma M, Dong Q, Hirano T, Kasner SE, Saver JL, Masjuan J, et al; OCEANIC-STROKE Investigators. Asundexian for Secondary Stroke Prevention. N Engl J Med. 2026;394(15):1467-1479. PubMed PMID: 41985132.   Butler CC, Pinto AD, Harris V, Holmes J, Rahman NM, Cureton L, et al; PANORAMIC Trial and CanTreatCOVID Trial Collaborative Groups. Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients. N Engl J Med. 2026;394(16):1583-1594. PubMed PMID: 42019019.   Guides de pratique :    Prescott HC, Antonelli M, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. Crit Care Med. 2026;54(4):725-812. PubMed PMID: 41869847.   Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154-e1276. PubMed PMID: 41824552.   Références du quiz clinique :   Öberg J, Buchwald P, Nilsson A, Nilson B, Inghammar M. Risk and prognosis of colorectal cancer following bacteraemia with Streptococcus bovis–Streptococcus equinus complex: A Swedish nationwide retrospective cohort study. Epidemiol Infect. 2025;154:e2. PubMed PMID: 41449806.   Abdulamir AS, Hafidh RR, Abu Bakar F. The association of Streptococcus bovis/gallolyticus with colorectal tumors: the nature and the underlying mechanisms of its etiological role. J Exp Clin Cancer Res. 2011;30(1):11. PubMed PMID: 21247505.

  4. Apr 27

    BC 077 – Comparaison des risques hémorragiques entre le rivaroxaban et l’apixaban dans le traitement de la maladie thromboembolique (étude COBRRA)

    Dans cette 77e baladodiffusion, les Drs Alexandre Mutchmore et Geneviève LeTemplier discutent du traitement de l’embolie pulmonaire, en plus de réviser la littérature médicale de mars 2026.   Quiz clinique (2 min 04), présentation principale (2 min 50), critique (21 min 43), retour sur le cas clinique (31 min 08), autres articles (33 min 45), réponse au quiz clinique (38 min 00).   Référence principale :   Castellucci LA, Chen VM, Kovacs MJ, Lazo-Langner A, Greenstreet P, Kahn S, et al; COBRRA Trial Investigators. Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism. N Engl J Med. 2026;394(11):1051-1060. PubMed PMID: 41812192.   Articles associés :    Moores LK. The COBRRA Trial – Ending the Venous Thromboembolism Safety Toss-up. N Engl J Med. 2026;394(11):1123-1124. PubMed PMID: 41812199.   EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-510. PubMed PMID: 21128814.   Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808. PubMed PMID: 23808982.   Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, Geersing GJ, et al. Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160(6):2247-2259. PubMed PMID: 34352279.   Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020 ;4(19):4693-4738. PubMed PMID: 33007077.   Autres articles d’intérêt récent :    Heerspink HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, Groop PH, Ji L, Jongs N, Mathieu C, Pratley RE, Rosas SE, Rossing P, Skyler JS, Tuttle KR, Lawatscheck R, Brinker M, Scheerer MF, Russell J, Schloemer P, McGill JB; FINE-ONE Investigators. Finerenone in Type 1 Diabetes and Chronic Kidney Disease. N Engl J Med. 2026;394(10):947-957. PubMed PMID: 41780000.   Azizi M, Brown JM, Dwyer JP, Flack JM, Jones ESW, Kurlyandskaya R, Li H, Birve F, Lihn AS, Perl S, Schlaich MP, Shibata H, Wang JG, Williams B; Bax24 investigators. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2026;407(10532):988-999. PubMed PMID: 41794437.   Zhang Y, Liu Y, Li Y, Li Y, Gu X, Kang JH, Eliassen AH, Wang M, Rimm EB, Willett WC, Hu FB, Stampfer MJ, Wang DD. Coffee and Tea Intake, Dementia Risk, and Cognitive Function. JAMA. 2026;335(11):961-974. PubMed PMID: 41661604.   Rosenstock J, Yabe D, Cox D, Li J, Denning M, Wu WS, Liu R, Zhao Y; ACHIEVE-3 Investigators. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet. 2026;407(10534):1147-1160. PubMed PMID: 41765029.   Guides de pratique :    Bajaj JS, Jakab SS, Jesudian AB, Rahimi RS, Duarte-Rojo A, Chen PH, Wong RJ, Tapper EB, Tandon P. ACG Clinical Guideline: Hepatic Encephalopathy. Am J Gastroenterol. 2026;121(3):588-618. PubMed PMID: 41773757.   Creager MA, Barnes GD, Giri J, Mukherjee D, Jones WS, Burnett AE, Carman T, Casanegra AI, Castellucci LA, Clark SM, Cushman M, de Wit K, Eaves JM, Fang MC, Goldberg JB, Henkin S, Johnston-Cox H, Kadavath S, Kadian-Dodov D, Keeling WB, Klein AJP, Li J, McDaniel MC, Moores LK, Piazza G, Prenger KS, Pugliese SC, Ranade M, Rosovsky RP, Russo F, Secemsky EA, Sista AK, Tefera L, Weinberg I, Westafer LM, Young MN. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(12):e977-e1051. PubMed PMID: 41712677.   Référence du quiz clinique :   Abramson BL, Al-Omran M, Anand SS, Albalawi Z, Coutinho T, de Mestral C, et al. Canadian Cardiovascular Society 2022 Guidelines for Peripheral Arterial Disease. Can J Cardiol. 2022;38(5):560-587. PubMed PMID: 35537813.

  5. Mar 20

    BC 076 – Seuils de D-dimères ajustés en fonction de l’âge pour exclure une thrombose veineuse profonde (étude ADJUST-DVT)

    Dans cette 76e baladodiffusion, les Drs Alexandre Mutchmore et Luc Lanthier discutent de diagnostic de la thrombose veineuse profonde, en plus de réviser la littérature médicale de janvier et février 2026.   Quiz clinique (1 min 45), présentation principale (2 min 15), critique (23 min 10), retour sur le cas clinique (30 min 25), autres articles (31 min 48), réponse au quiz clinique (36 min 55).   Référence principale :   Le Gal G, Robert-Ebadi H, Thiruganasambandamoorthy V, Moustafa F, Penaloza A, Catella J, et al. Age-Adjusted D-Dimer Cutoff Levels to Rule Out Deep Vein Thrombosis. JAMA. 2026;335(5):416-24. PubMed PMID: 41490105.   Articles associés :    Righini M, Van Es J, Den Exter PL, Roy PM, Verschuren F, Ghuysen A, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA. 2014;311(11):1117-24. PubMed PMID: 24643601.   Ujueta F, Piazza G. Like a Fine Wine-Aging the D-Dimer to Improve Value and Clinical Efficiency. JAMA. 2026;335(5):403-4. PubMed PMID: 41490683.   Lim W, Le Gal G, Bates SM, Righini M, Haramati LB, Lang E, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Adv. 2018;2(22):3226-56. PubMed PMID: 30482764.   https://thrombosiscanada.ca/hcp/practice/clinical_guides?language=en-ca&guideID=DEEPVEINTHROMBOSISDIAGNOSIS   https://acforum.org/web/resource_files/1772710804-36404.pdf   Autres articles d’intérêt récent :    Lok CE, Farkouh M, Hemmelgarn BR, Moist LM, Polkinghorne KR, Tomlinson G, et al. Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis. N Engl J Med. 2026;394(2):128-37. PubMed PMID: 41201837.   Verma A, Birnie DH, Jiang C, Heidbuchel H, Hindricks G, Kirchhof P, et al. Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation. N Engl J Med. 2026;394(4):323-32. PubMed PMID: 41211931.   Wong CX, Cheung CC, Montenegro G, Oo HH, Pena IJ, Tang JJ, et al. Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial. JAMA. 2026;335(4):317-25. PubMed PMID: 41206802.   Marston NA, Bergmark BA, Alexander VJ, Prohaska TA, Kang YM, Moura FA, et al. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. N Engl J Med. 2026;394(5):429-41. PubMed PMID: 41211918.   Navar AM, Mikhailova E, Catapano AL, Banka P, Blom DJ, Cadena A, et al. A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. N Engl J Med. 2026;394(6):529-39.    Lee SJ, Yu HT, Lee YJ, Lee SH, Heo JH, Ahn SG, et al. Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents. N Engl J Med. 2026;394(7):658-68. PubMed PMID: 41211917.   Rana AI, Zheng L, Castillo-Mancilla J, Bao Y, Sieczkarski S, Brooks KM, et al. Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges. N Engl J Med. 2026;394(9):858-71. PubMed PMID: 41707171.   Guides de pratique :    American Diabetes Association Professional Practice Committee for D. Summary of Revisions: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(1 Suppl 1):S6-S12. PubMed PMID: 41358896.   Andrade JG, Joza J, Chew DS, Ayala-Paredes F, Bennett MT, Essebag V, et al. The Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Selection, Implantation, and Management of Patients With Cardiac Implantable Electronic Devices. Can J Cardiol. 2026;42(1):1-68. PubMed PMID: 41539743.   Babitt JL, Berns JS, Bozkurt B, Cheung Khedairy RS, Cuevas Y, Effa EE, et al. Executive Summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD). Kidney Int. 2026;109(1):44-56. PubMed PMID: 41485807.   Mahadevan U, Seow CH, Barnes EL, Chaparro M, Flanagan E, Friedman S, et al. Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease. Am J Gastroenterol. 2026;121(1):31-79. PubMed PMID: 40862489.   Références du quiz clinique :   Sconfienza E, Tetti M, Forestiero V, Veglio F, Mulatero P, Monticone S. Prevalence of Functioning Adrenal Incidentalomas: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2023;108(7):1813-1823. PubMed PMID: 36718682.   Fassnacht M, Tsagarakis S, Terzolo M, Tabarin A, Sahdev A, Newell-Price J, Pelsma I, Marina L, Lorenz K, Bancos I, Arlt W, Dekkers OM. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023;189(1):G1-G42. PubMed PMID: 37318239.   Kebebew E. Adrenal Incidentaloma. N Engl J Med. 2021;384(16):1542-1551. PubMed PMID: 33882207.

  6. Jan 24

    BC 075 – Traitement médical ou par revascularisation dans la sténose carotidienne asymptomatique (étude CREST-2)

    Dans cette 75e baladodiffusion, les Drs Alexandre Mutchmore et Luc Lanthier discutent du traitement de la sténose carotidienne asymptomatique, en plus de réviser la littérature médicale de décembre 2025.   Quiz clinique (3 min 30), présentation principale (4 min 32), critique (32 min 22), retour sur le cas clinique (41 min 51), autres articles (45 min 57), réponse au quiz clinique (49 min 26).   Référence principale :   Brott TG, Howard G, Lal BK, Voeks JH, Turan TN, Roubin GS, et al. Medical Management and Revascularization for Asymptomatic Carotid Stenosis. N Engl J Med. 2026;394(3):219-31. PubMed PMID: 41269206.   Articles associés :    Brown MM, Bonati LH. Managing Asymptomatic Carotid Stenosis. N Engl J Med. 2026;394(3):296-97. PubMed PMID: 41269202.   North American Symptomatic Carotid Endarterectomy Trial Collaborators; Barnett HJM, Taylor DW, Haynes RB, Sackett DL, Peerless SJ, Ferguson GG, Fox AJ, Rankin RN, Hachinski VC, Wiebers DO, Eliasziw M. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325(7):445-53. PubMed PMID: 1852179.   Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet. 1998;351(9113):1379-87. PubMed PMID: 9593407.   Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA. 1995;273(18):1421-8. PubMed PMID: 7723155.   Halliday A, Mansfield A, Marro J, Peto C, Peto R, Potter J, Thomas D; MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet. 2004;363(9420):1491-502. PubMed PMID: 15135594.   Naylor R, Rantner B, Ancetti S, de Borst GJ, De Carlo M, Halliday A, et al. Editor’s Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. Eur J Vasc Endovasc Surg. 2023;65(1):7-111. PubMed PMID: 35598721.   Bushnell C, Kernan WN, Sharrief AZ, Chaturvedi S, Cole JW, Cornwell WK, 3rd, et al. 2024 Guideline for the Primary Prevention of Stroke: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2024;55(12):e344-e424. PubMed PMID: 39429201.   Reiff T, Eckstein HH, Mansmann U, Jansen O, Fraedrich G, Mudra H, et al; SPACE-2 Investigators. Carotid endarterectomy or stenting or best medical treatment alone for moderate-to-severe asymptomatic carotid artery stenosis: 5-year results of a multicentre, randomised controlled trial. Lancet Neurol. 2022;21(10):877-888. PubMed PMID: 36115360.   Howard DPJ, Gaziano L, Rothwell PM, Oxford Vascular S. Risk of stroke in relation to degree of asymptomatic carotid stenosis: a population-based cohort study, systematic review, and meta-analysis. Lancet Neurol. 2021;20(3):193-202. PubMed PMID: 33609477.   Donners SJA, van Velzen TJ, Cheng SF, Gregson J, Hazewinkel AD, Pizzini FB, et al. Optimised medical therapy alone versus optimised medical therapy plus revascularisation for asymptomatic or low-to-intermediate risk symptomatic carotid stenosis (ECST-2): 2-year interim results of a multicentre randomised trial. Lancet Neurol. 2025;24(5):389-99. PubMed PMID: 40252662.   Autres articles d’intérêt récent :    Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393(24):2409-20. PubMed PMID: 41406444.   Kougias P, Sharath SE, Zhan M, Carson JL, Norman LE, Mi Z, et al. Liberal or Restrictive Postoperative Transfusion in Patients at High Cardiac Risk: The TOP Randomized Clinical Trial. JAMA. 2025;334(24):2197-207. PubMed PMID: 41205227.   Horn DB, Ryan DH, Kis SG, Alves B, Mu Y, Kim SG, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2026;406(10522):2927-44. PubMed PMID: 41275875.   Xie M, Eyting M, Bommer C, Ahmed H, Geldsetzer P. The effect of shingles vaccination at different stages of the dementia disease course. Cell. 2025;188(25):7049-64 e20. PubMed PMID: 41338191.   Guides de pratique :    Tan DHS, Hull MW, Onyegbule SO, Ajiboye W, Arkell C, Baril JG, et al. Canadian guideline on HIV pre- and postexposure prophylaxis: 2025 update. CMAJ. 2025;197(41):E1374-E91. PubMed PMID: 41326046.   Scott FI, Ananthakrishnan AN, Click B, Agrawal M, Syal G, Haydek JP, et al. AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn’s Disease. Gastroenterology. 2025;169(7):1397-448. PubMed PMID: 41274746.   Orman ES, Fortune BE, John BV, Asrani SK. AGA Clinical Practice Update on the Management of Ascites, Volume Overload, and Hyponatremia in Cirrhosis: Expert Review. Gastroenterology. 2025;169(7):1547-57. PubMed PMID: 41114681.   Référence du quiz clinique :   Rajkumar SV, Kumar S. Monoclonal Gammopathy of Undetermined Significance. N Engl J Med. 2025 Oct 2;393(13):1315-1326. PubMed PMID: 41032708.

  7. 12/17/2025

    BC 074 – Évolocumab chez les patients à risque cardiovasculaire élevé (étude VESALIUS-CV)

    Dans cette 74e baladodiffusion, les Drs Alexandre Mutchmore et Luc Lanthier discutent de l’efficacité de l’évolocumab, un inhibiteur des PCSK9, chez les sujets à haut risque cardiovasculaire, en plus de réviser la littérature médicale d’octobre et novembre 2025.   Quiz clinique (4 min 16), présentation principale (5 min 28), critique (27 min 19), retour sur le cas clinique (37 min 43), autres articles (40 min 32), réponse au quiz clinique (45 min 45).   Référence principale :   Bohula EA, Marston NA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, et al; VESALIUS-CV Investigators. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. N Engl J Med. 2025 Nov 8. doi: 10.1056/NEJMoa2514428. Epub ahead of print. PubMedPMID: 41211925.   Articles associés :    Ibanez B, Latini R, Rossello X, Dominguez-Rodriguez A, Fernández-Vazquez F, Pelizzoni V, et al. Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction. N Engl J Med. 2025;393(19):1889-1900. PubMed PMID: 40888702.   Munkhaugen J, Kristensen AMD, Halvorsen S, Holmager T, Olsen MH, Bakken A, et al. Beta-Blockers after Myocardial Infarction in Patients without Heart Failure. N Engl J Med. 2025;393(19):1901-1911. PubMed PMID: 40888716.   Rossello X, Prescott EIB, Kristensen AMD, Latini R, Fuster V, Fagerland MW, et al. β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials. Lancet. 2025;406(10508):1128-1137. PubMed PMID: 40897190.   Kristensen AMD, Rossello X, Atar D, Yndigegn T, Kimura T, Latini R, et al; Beta-Blocker Trialists’ Collaboration Study Group.. Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction. N Engl J Med. 2025 Nov 9. doi: 10.1056/NEJMoa2512686. Epub ahead of print. PubMed PMID: 41211954.   Deanfield J, Lincoff AM, Kahn SE, Emerson SS, Lingvay I, Scirica BM, et al.  Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet. 2025;406:2257-2268. PubMed PMID: 41138739.   Ndumele CE, Blumenthal RS. VESALIUS and the Anatomy of High-Risk Prevention. N Engl J Med. 2025;393(19):eEditorial. doi:10.1056/NEJMe2515447. PubMed PMID: 41211946.   Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. PubMed PMID: 28304224.   Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-2107. PubMed PMID: 30403574.   Autres articles d’intérêt récent :    Kim D, Shim J, Choi EK, Oh IY, Kim J, Lee YS, et al. Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial. JAMA. 2025;334(14):1246-1254. PubMed PMID: 40886309.   Lemesle G, Didier R, Steg PG, Simon T, Montalescot G, Danchin N, et al. Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation: The AQUATIC Trial. N Engl J Med. 2025;393(16):1578-1588. PubMed PMID: 40888725.   Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ES, et al. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025;393(14):1363-1374. PubMed PMID: 40888730.   McLaughlin VV, Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, et al. Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis. N Engl J Med. 2025;393(16):1599-1611. PubMed PMID: 41025556.   Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393(18):1796-1806. PubMed PMID: 40960239.   Guimarães PO, Franken M, Tavares CAM, Antunes MO, Silveira FS, Andrade PB, et al. Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes. N Engl J Med. 2025;393(21):2095-2106. PubMed PMID: 40888723.   Tarantini G, Honton B, Paradies V, Lemesle G, Range G, Godin M, et al. Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction. N Engl J Med. 2025;393(21):2083-2094. PubMed PMID: 40888726.   Fitz-Patrick D, McVinnie DS, Jackson LA, Crowther G, Geevarughese A, Cannon KD, et al; Pfizer C4781004 Trial Investigators. Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine. N Engl J Med. 2025;393(20):2001-2011. PubMed PMID: 41259756.   Guides de pratique :    Virani S, Zieroth S, Aleksova N, Anderson K, Clarke B, Ducharme A, Ezekowitz JA, Foroutan F, Giannetti N, Jain R, et al. Canadian Cardiovascular Society/Canadian Heart Failure Society 2025 Guideline Update for Pharmacologic Management of Heart Failure With Nonreduced Ejection Fraction (LVEF > 40%). Can J Cardiol. 2025;41(10):1857-74. PubMed PMID: 41110921.   Shih AW, Schnell G, Belley-Côté E, Lett R, Peretz-Larochelle M, Tinmouth A. Canadian Cardiovascular Society and National Advisory Committee on Blood and Blood Products Joint Statement on Blood Utilization and Transfusion for Patients With Acute Coronary Syndromes. Can J Cardiol. 2025;41(10):1875–1884. PubMed PMID: 41110922.   Schulz-Menger J, Collini V, Gröschel J, Adler Y, Brucato A, Christian V, Ferreira VM, Gandjbakhch E, Heidecker B, Kerneis M, et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis: Developed by the task force for the management of myocarditis and pericarditis of the European Society of Cardiology (ESC) endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2025;46(40):3952-4041. PubMed PMID: 40878297.   Staller K, Parkman HP, Greer KB, Leiman DA, Zhou MJ, Singh S, Camilleri M, Altayar O; AGA Clinical Guidelines Committee. AGA Clinical Practice Guideline on Management of Gastroparesis. Gastroenterology. 2025;169(5):828-61. PubMed PMID: 40976635.   Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group. KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int. 2025;108(4S):S1–S71. PubMed PMID: 40975564.   Praz F, Borger MA, Lanz J, Marin-Cuartas M, Abreu A, Adamo M, et al. 2025 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2025;46(44):4635-4736. PubMed PMID: 40878295.   Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, Benn M, Binder CJ, Catapano AL, De Backer GG, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359-78. PubMed PMID: 40878289.   Wani S, Zhou MJ, Sawas T, Rubenstein JH, Eluri S, Leiman DA, Sultan S, Singh S, Inadomi J, Thrift AP, Katzka DA, Davitkov P. AGA Clinical Practice Guideline on Surveillance of Barrett’s Esophagus. Gastroenterology. 2025;169(6):1184-1231. PubMed PMID: 41125322.   Référence du quiz clinique :   Gallant RC, Cameron L, Mithoowani S. Copper deficiency. CMAJ. 2025;197(16):E456. PubMed PMID: 40294944.

  8. 10/28/2025

    BC 073 – Altéplase dans l’AVC ischémique aigu entre 4,5 et 24 heures (étude HOPE)

    Dans cette 73e baladodiffusion, les Drs Luc Lanthier et Emmanuelle Lapointe discutent du traitement thrombolytique retardé dans l’AVC ischémique aigu, en plus de réviser la littérature médicale de juillet, août et septembre 2025.   Quiz clinique (2 min 16), présentation principale (2 min 38), critique (26 min 42), retour sur le cas clinique (36 min 05), autres articles (37 min 50), réponse au quiz clinique (44 min 57)   Référence principale :   Zhou Y, He Y, Campbell BCV, Liebeskind DS, Yuan C, Chen H, et al. Alteplase for Acute Ischemic Stroke at 4.5 to 24 Hours: The HOPE Randomized Clinical Trial. JAMA. 2025;334(9):788-97. PubMed PMID: 40773205.   Articles associés :    Thomalla G, Simonsen CZ, Boutitie F, Andersen G, Berthezene Y, Cheng B, et al. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset. N Engl J Med. 2018;379(7):611-22. PubMed PMID: 29766770.   Ma H, Campbell BCV, Parsons MW, Churilov L, Levi CR, Hsu C, et al. Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke. N Engl J Med. 2019;380(19):1795-803. PubMed PMID: 31067369.   Albers GW, Jumaa M, Purdon B, Zaidi SF, Streib C, Shuaib A, et al. Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection. N Engl J Med. 2024;390(8):701-11. PubMed PMID: 38329148. Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy. N Engl J Med. 2024;391(3):203-12. PubMed PMID: 38884324.   Wang Z, Li J, Wang X, Yuan B, Li J, Ma Q. Tenecteplase for Acute Ischemic Stroke at 4.5 to 24 Hours: A Meta-Analysis of Randomized Controlled Trials. Stroke. 2025 Oct 13. doi: 10.1161/STROKEAHA.125.053256. PubMed PMID: 41078125.   Autres articles d’intérêt récent :    Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26-36. PubMed PMID: 40353578.   Kahlmann V, Janssen Bonas M, Moor CC, Grutters JC, Mostard RLM, van Rijswijk H, et al. First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate. N Engl J Med. 2025;393(3):231-42. PubMed PMID: 40387020.   Desai AS, Karns AD, Badariene J, Aswad A, Neutel JM, Kazi F, et al. Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial. JAMA. 2025;334(1):46-55. PubMed PMID: 40434761.   Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, et al. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025;393(6):533-43. PubMed PMID: 40470996.   McIntyre L, Fergusson D, McArdle T, English S, Cook DJ, Fox-Robichaud AE, et al. A Crossover Trial of Hospital-Wide Lactated Ringer’s Solution versus Normal Saline. N Engl J Med. 2025;393(7):660-70. PubMed PMID: 40503714.   Davies MJ, Bajaj HS, Broholm C, Eliasen A, Garvey WT, le Roux CW, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025;393(7):648-59. PubMed PMID: 40544432.   Garvey WT, Bluher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietilainen KH, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025;393(7):635-47. PubMed PMID: 40544433.   Ding D, Nguyen B, Nau T, Luo M, Del Pozo Cruz B, Dempsey PC, et al. Daily steps and health outcomes in adults: a systematic review and dose-response meta-analysis. Lancet Public Health. 2025;10(8):e668-e81. PubMed PMID: 40713949.   Tonet E, Raisi A, Zagnoni S, Chiaranda G, Pasanisi G, Aschieri D, et al. Multidomain Rehabilitation for Older Patients with Myocardial Infarction. N Engl J Med. 2025;393(10):973-82. PubMed PMID: 40879431.   Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025;393(11):1065-76. PubMed PMID: 40544435.   Tao C, Liu T, Cui T, Liu J, Li Z, Ren Y, et al. Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke. N Engl J Med. 2025;393(12):1191-201. PubMed PMID: 40616232.   Bavendiek U, Grosshennig A, Schwab J, Berliner D, Rieth A, Maier LS, et al. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2025;393(12):1155-65. PubMed PMID: 40879434.   Piazza G, Bikdeli B, Pandey AK, Krishnathasan D, Khairani CD, Bejjani A, et al. Apixaban for Extended Treatment of Provoked Venous Thromboembolism. N Engl J Med. 2025;393(12):1166-76. PubMed PMID: 40888734.   Florian J, Salcedo P, Burkhart K, Shah A, Chekka LMS, Keshishi D, et al. Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial. JAMA Intern Med. 2025;185(9):1070-8. PubMed PMID: 40622698.   Guides de pratique :    Podolanczuk AJ, Hunninghake GM, Wilson KC, Khor YH, Kheir F, Pang B, et al. Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement. Am J Respir Crit Care Med. 2025;211(7):1132-55. PubMed PMID: 40387336.   Adler GK, Stowasser M, Correa RR, Khan N, Kline G, McGowan MJ, et al. Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2025;110(9):2453-95. PubMed PMID: 40658480.   Pedersen SD, Manjoo P, Dash S, Jain A, Pearce N, Poddar M. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update. CMAJ. 2025;197(27):E797-E809. PubMed PMID: 40789597.   Thombs BD, Traversy G, Reynolds DL, Lang E, Groulx S, Wilson BJ, et al. Recommendations on interventions for tobacco smoking cessation in adults in Canada. CMAJ. 2025;197(28):E846-E61. PubMed PMID: 40854602   Writing Committee M, Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;152(11):e114-e218. PubMed PMID: 40811497.   Référence du quiz clinique :   Livingston G, Huntley J, Liu KY, Costafreda SG, Selbaek G, Alladi S, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572-628. PubMed PMID: 39096926.

See All (50)

About

BaladoCritique – club de lecture médical | médecine interne | EBM

Information

You Might Also Like